In the present report we describe a patient with multiple myeloma and long-standing paraproteinemia who developed xanthoma in the absence of an elevation in plasma cholesterol or triglyceride concentrations. Studies demonstrated that our patient's monoclonal IgG antibody interacted with apoprotein B-100. The LDL-antibody complex isolated from our patient did not affect the degradation of LDL by human fibroblasts, indicating that while IgG derived from our patient interacted with LDL it did not alter the metabolism of this lipoprotein by the LDL receptor pathway. Since the LDL receptor pathway is the major route of LDL metabolism, this probably explains why our patient was not hyperlipidemic. In contrast to an absence of effect on the LDL receptor, our patient's LDL-antibody complex stimulated cholesterol esterification within macrophages indicating the uptake and degradation of the LDLantibody complex. The LOL-antibody complex inhibited the degradation of acetyl LDL by macrophages (scavenger pathway), demonstrating that our patient's LDL-antibody complex was recognized as a modified LDL. Moreover, mixing Ig from our patient with normal LDL also resulted in the normal LDL increasing the esterification of cholesterol by macrophages.
Introduction
Cutaneous xanthoma occurring in association with paraproteinemia is a well-documented clinical abnormality that is seen in patients with multiple myeloma, benign monoclonal gammapathies, and other reticular endothelial disorders (1) (2) (3) (4) (5) (6) . In many of these individuals the occurrence of xanthoma is associated with hyperlipidemia, but it should be recognized that cutaneous xanthoma in association with paraproteinemia can be observed in individuals whose plasma lipid levels are within the normal range (1, 3, 5, (7) (8) (9) .
The association of paraproteinemia with hyperlipidemia could occur through a variety of mechanisms. In some cases the simultaneous occurrence of a familial disorder of lipid metabolism unrelated to paraproteinemia may be the basis for the hyperlipidemia (10) . In other instances inhibition of heparin-induced lipoprotein lipase activity by an antibody has been observed, and this may be the underlying abnormality accounting for the hyperlipidemia (5, 1 1). It is more likely, however, that the majority of cases of hyperlipidemia that occur in association with paraproteinemia are secondary to the direct interaction of Ig with lipoproteins. Several studies have shown that Ig obtained from patients with reticular endothelial disorders interact with lipoproteins (4) (5) (6) (12) (13) (14) . Furthermore, such interactions can result in alterations in lipoprotein metabolism. Baudet et al. have described the effect of IgA isolated from three patients with multiple myeloma, hyperlipidemia, and xanthomatosis on the metabolism of LDL in fibroblasts (15) . These investigators observed that the IgA isolated from two of their patients blocked the LDL-induced feedback inhibition of cholesterol synthesis that is characteristically observed in fibroblasts incubated with LDL. This suggests that the antibody may have induced the hyperlipidemia by interfering with the metabolism of LDL by the LDL receptor pathway. Cortese et al. have described two patients with type III hyperlipidemia and xanthomatosis in association with myelomatosis whose LDL failed to bind to the LDL receptor of lymphocytes in vitro (16) . They further showed in in vivo studies a greatly reduced fractional catabolic rate of IDL and a prolonged IDL' to LDL conversion time that was postulated to be due to inhibition of IDL binding to the LDL receptor. The results from these two studies support the concept that a direct interaction of Ig with lipoprotein may alter the metabolism of lipoproteins and thus result in the hyperlipidemia observed in some patients with paraproteinemia.
In contrast to the information available addressing the possible mechanisms by which paraproteinemia results in elevated lipid levels, studies of the pathophysiological basis for the xanthomas in the absence of hyperlipidemia in patients with paraproteinemia are few. In the present manuscript we describe a patient with elevated Ig who had numerous xanthomas for many years in the absence of hyperlipidemia. We 1969, 1978, 1978, and 1980 .
Xanthomata were first noted in the inguinal and periaxillary regions in 1972. The lesions were yellow nodules -3 mm-1.5 cm in size (Fig. 1) . The underlying skin also had a diffuse yellow coloration. Biopsy of a nodule in 1976 revealed fibrous tissue with a proliferation of histocytes and foam cells (Fig. 2) . The size and number of lesions have remained relatively constant with time.
From 1969 to 1983 seven plasma cholesterol determinations were obtained that ranged from 152) to 285 mg/dl with an average of 221 ± 15.6 (SEM). Five plasma triglyceride determinations ranged between 76 and 159 mg/dl with an average of 104±14.4. On several occasions the lipoprotein electrophoretic pattern was normal. The patient did not have any known relatives with either elevations in plasma lipid levels or xanthoma. The patient did not have a history of atherosclerotic vascular disease.
On physical examination vital signs were normal. The carotids were normal without bruits. The heartbeat was regular with a grade 2 over 6 systolic murmur at the second right intercostal space. On abdominal examination the liver was firm with a smooth edge and was 16 cm in span. A firm spleen was felt 3 cm below the left costal margin. No abdominal or femoral bruits were heard and femoral pulses were normal. Pulses in the distal extremities were also normal. The back was tender over the L-3 and L-4 region. Numerous yellow-orange nodules 0. Methods 20 ml ofblood was obtained from the patient on several occasions. The plasma was separated by centrifugation and kept at room temperature until lipoproteins and circulating antibodies were separated by the methods described below, becauseinitial studies demonstrated that the antibody precipitated in the cold. The effect of temperature on the Ig-lipoprotein complex is shown in Fig. 3 . At -70C there is a rapid rise in optical density indicating protein precipitation. The plasma was passed over an ion exchange column (DE-52; Whatman Laboratory Products, Inc., Clifton, NJ) equilibrated with 0.0175 M sodium phosphate (pH 6.3). Elution with the same buffer resulted in the separation of two protein peaks, a fraction that contained Ig alone and a slower migrating fraction that contained both Ig and apo B-containing lipoproteins (Fig. 4) . To quantitate the proportion of apoprotein B-con- Human fibroblasts were obtained from the University ofCalifornia Tissue Culture facility and were grown in Eagle's MEM containing 10% FCS to near confluence then transferred to a medium containing 10% lipoprotein-deficient serum for 48 h. Lipoprotein-deficient serum was prepared from the plasma of normal fasting subjects by ultracen- trifugation at a density of 1.24 g/ml (17) . LDL was isolated from the plasma of normal fasting subjects by ultracentrifugation between densities 1.019 and 1.063 g/ml (17) . The LDL was radiolabeled with 1251 using the monochloride method of McFarlane (18) . The ( 19) . The degradation ofacetylated LDL was determined in mouse peritoneal macrophages. LDL was acetylated with acetic anhydride as described by Basu et al. and the acetyl LDL was radiolabeled with 125I using the monochloride method of McFarlane (18, 21) . The degradation of the '25l-labeled acetyl LDL was determined as described above for labeled LDL. In addition the 'l25-labeled acetyl LDL was-used to determine if our patient's antibody bound to acetyl LDL. Serum was incubated overnight at 40C with 1251-labeled acetq LDL followed by the addition of protein A beads (protein A:IgGsorb from the Enzyme Center, Inc., Malden, MA). After a 1-h incubation the labeled acetyl LDL bound to antibody were separated by centrifugation, washed several times by centrifugation, and counted.
Purified apoproteins, antibodies to these apoproteins, and lipoproteins were prepared as described in an earlier publication (22 The interaction of our patient's Ig with apoprotein B-containing lipoproteins isolated from normals is shown in Fig. 5 . As is apparent from the figure, our patient's Ig bound with high affinity to LDL and with much less affinity to VLDL and chylomicrons, which also contain apoprotein B. This suggests that the epitope of apoprotein B to which the Ig binds is less 1- We next determined the effect of our patient's serum on the degradation of '25I-labeled LDL by fibroblasts. As shown in Fig. 6 , the Ig-LDL complex obtained from our patient inhibited the degradation oflabeled LDL to a similar degree as LDL obtained from normal subjects. Additionally, the combining of normal LDL and our patient's Ig also resulted in the inhibition of the degradation of labeled LDL, whereas Ig alone had no effect on labeled LDL degradation. These studies indicate that the LDL-Ig complex obtained from our patient reacts with the LDL receptor in a manner similar to that of normal uncomplexed LDL, i.e., that complex formation does not interfere with the receptor binding site.
The effect of our patient's Ig and his Ig-lipoprotein complex on the formation ofcholesterol esters in mouse peritoneal macrophages was determined next (Fig. 7) . The incorporation of oleate into cholesterol esters is a sensitive index ofthe delivery of cholesterol to macrophages and has been shown to be increased in a variety of circumstances that result in the increased uptake of cholesterol by macrophages (23, 24) . The Ig-lipoprotein complex isolated from our patient resulted in an increase in the incorporation of [3H]oleate into cholesterol esters. Similarly, normal LDL mixed with our patient's Ig resulted in an increase in cholesterol ester formation. These results indicate that our patient's Ig-LDL complex results in an increased delivery of cholesterol to the macrophage.
The macrophage is known to possess a scavenger receptor reactive with chemically modified LDL such as acetyl LDL (20, 23) . This receptor is distinct from that which catabolizes native unmodified LDL. To determine whether our patient's complex interacted with the scavenger receptor, the effect of our patient's Ig lipoprotein complex on the degradation of acetyl '251I-labeled LDL by macrophages was determined (Fig.  8) was incubated overnight at 4VC with our patient's serum and the interaction determined as described in Methods. Similar to our observations for LDL described above, our patient's Ig was able to bind to acetyl LDL. Circulating antibody was reactive to a nearly equivalent extent with both native and acetyl LDL. The ratio of apoprotein B precipitated under equivalent conditions was 1.3 (native LDL/acetyl LDL). As shown in Fig. 8 , this did not affect the degradation of acetyl LDL by macrophages, which is analogous to the results shown in Fig. 6 where our patient's Ig alone did not affect LDL degradation in fibroblasts. These results indicate that the Ig-LDL complex interacts with the acetyl LDL receptor of macrophages and thereby interferes with the interiorization of labeled acetyl LDL.
Discussion
Numerous studies have demonstrated that Ig can interact with apoproteins and lipoproteins (4) (5) (6) (12) (13) (14) . In a few instances these interactions have been shown to alter the metabolism of lipoproteins. Baudet et al. have demonstrated that an IgA isolated from patients with multiple myeloma, hyperlipidemia, and xanthomas blocked the binding of LDL to the LDL receptor of fibroblasts (15) . Similarly, Cortese et al. have demonstrated that the LDL from two patients with multiple myeloma, type III hyperlipidemia, and xanthomas did not bind to the LDL receptor of lymphocytes (16) . Thus, the interactions of Ig with lipoproteins can result in an alteration of lipoprotein metabolism. It is likely that the interference by antibody of LDL metabolism by the LDL receptor pathway, the major pathway of LDL metabolism (25) , would significantly affect plasma lipid levels and could account for the hyperlipidemia in these patients.
In the present manuscript we describe a patient who had numerous xanthomata for more than a decade in association with paraproteinemia. Over this period of time numerous plasma cholesterol and triglyceride measurements were obtained that did not demonstrate the presence of hyperlipidemia. The mechanism by which xanthoma occur in association with paraproteinemia in the absence of hyperlipidemia to our knowledge has only been explored in a single study. In 1981 Groszak et al. reported, based on in vivo turn over studies, that there was an increased rate of clearance of VLDL triglyceride and chylomicrons in a patient with normolipidemic xanthomatosis associated with benign monoclonal gammapathy (9) . These authors postulated that an enhanced tissue uptake and increased lipolysis due to the interaction of antibody with triglyceride-rich lipoproteins could possibly be the underlying mechanism accounting for the xanthoma.
In This property is the opposite of that previously reported for circulating anti-LDL-Ig, presumably because in the present case the epitope on apo B-100 recognized is not located at or adjacent to the receptor binding site. In contrast to the absence ofan affect on the LDL receptor pathway we found that our patient's LDL-antibody complex delivered cholesterol to macrophages. When mouse peritoneal macrophages are incubated with human LDL they do not take up or degrade a great deal ofthe native lipoprotein (20, 23, 26) . However, LDL that is treated with acetic anhydride, which acetylates the amino group of lysine, does bind to mouse peritoneal macrophages (20, 23) . These distinct binding sites for acetyl LDL are of high affinity and saturable, and lead to the internalization of LDL through endocytosis (scavenger pathway of LDL metabolism) (20, 22) . Within the cell the LDL is digested in lysosomes with the release of cholesterol which is rapidly reesterified (23) . Acetyl LDL does not bind to the LDL receptor on fibroblasts (20, 23) . The LDL antibody complex from our patient stimulated cholesterol esterification within macrophages, indicating the uptake and degradation of the LDL antibody complex by macrophages (Fig. 7) . Additionally, as shown in Fig. 8 the LDL-antibody complex from our patient also inhibited the degradation of '25I-acetyl LDL by macrophages, demonstrating that our patient's LDL-antibody complex was recognized as a modified LDL by the acetyl LDL receptor on macrophages (scavenger pathway). Moreover, mixing Ig from our patient with normal LDL results in the normal LDL also increasing the esterification of cholesterol in macrophages (Fig. 7) and in a single experiment, inhibiting the degradation of '251I-acetyl LDL by macrophages (Fig. 8 ). These observations indicate that the monoclonal IgG from our patient is capable ofbinding with LDL in a manner such that the LDL-antibody complex is recognized by the acetyl LDL receptor of macrophages.
Our observations indicate that our patient's LDL-Ig complex is taken up by macrophages to a greater extent than normal LDL, and this could account for the occurrence of xanthoma in the absence of hyperlipidemia. The mechanism of uptake of our patient's LDL-Ig complex by macrophages has not been definitely demonstrated in these studies, but our results do indicate that the LDL-Ig complex is recognized by the acetyl-LDL receptor. This raises the possibility that the increased uptake is due to the interaction ofthe LDL-Ig complex with the acetyl-LDL receptor, but clearly other potential avenues of uptake could be operative. Our patient did not have any clinically apparent atherosclerotic vascular disease despite the long duration of extensive cutaneous xanthoma, and this raises the possibility that the uptake of LDL by macrophages does not by itself lead to an increased occurrence of vascular disease.
In summary, this study presents evidence that the interaction of antibody with LDL can increase the uptake of LDL by macrophages and thereby perhaps result in the clinical syndrome of xanthomatosis in association with paraproteinemia in the absence of hyperlipidemia.
